Blood cancers

Australians lead ‘warp speed’ trials for new BTKi in Waldenström

The potential of zanubrutinib in the management of patients with Waldenström macroglobulinemia (WM) has been highlighted in two international studies led by Australians. Professor Judith Trotman, from Concord Hospital and the University of Sydney, led a 3-year follow-up of the BTK inhibitor in a phase 1/2 study in WM. The study, published in Blood, comprised ...

Already a member?

Login to keep reading.

© 2021 the limbic